← Oncology Approval Tracker

FDA DECISION ·

Koselugo

selumetinib · AstraZeneca Pharmaceuticals

FDA approvalNew formulationNF1-associated plexiform neurofibromas
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Oral granules and capsules for children age 1 year or older with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas.

LAMPGEN ANALYSIS

Why it matters

Exposure data bridged the new granules to capsules and supported extending treatment of these benign tumors to age 1.

What research teams should watch

Train caregivers in formulation-specific preparation and check body surface area, ocular monitoring, and medication handling.

PRIMARY RECORDS

Sources